CDT Equity Expands Tapinarof Patent Portfolio with Two New Filings, Paving the Way for Second-Generation Product and Broader Clinical Scope.

CDT Equity has filed two new patent applications expanding its intellectual property portfolio for tapinarof, a drug approved for psoriasis and atopic dermatitis. The patents cover combination therapies and novel cocrystal forms of tapinarof, potentially enhancing its formulation properties and efficacy. This could extend tapinarof's lifecycle, broaden its clinical and commercial scope, and create opportunities for out-licensing. CDT plans to pursue out-licensing opportunities with pharmaceutical companies and specialist partners in dermatology and related therapeutic areas.